Trial Profile
A Randomized, Double-blind, Sponsor Open, Placebo-controlled, 52 Week Study Evaluating the Effect of Danirixin (GSK1325756) on Lung Function and Health Related Quality of Life in Participants With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 28 Jun 2023
Price :
$35
*
At a glance
- Drugs Danirixin (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors GlaxoSmithKline
- 04 Feb 2019 Status changed from recruiting to discontinued.
- 19 Apr 2018 Planned End Date changed from 13 Jun 2019 to 30 Oct 2019.
- 19 Apr 2018 Planned primary completion date changed from 13 Jun 2019 to 30 Oct 2019.